阿托伐他汀联合胺碘酮治疗原发性高血压伴阵发性房颤的研究  

The study of treatment of atorvastafin on hypertension with paroxysmal atrial fibrillation

作　　者：熊攀[1] 周莉[1] 侯玉娟[1] 

机构地区：[1]泰山医学院附属聊城市第二人民医院,252600

出　　处：《中国临床实用医学》2010年第4期16-18,共3页China Clinical Practical Medicine

摘　　要：目的探讨阿托伐他汀治疗原发性高血压伴阵发性心房颤动的疗效及对左心房内径、C反应蛋白（CRP）的影响。方法入选原发性高血压伴阵发性心房颤动患者80例，随机分成两组：对照组40例；阿托伐他汀组40例。均服药1年。观察两组治疗前后疗效及左心房内径、C反应蛋白的变化。结果①两组治疗后，对照组有效率38．4％，阿托伐他汀组有效率62．5％（χ^2=4．56P〈0．05）；②两组治疗后比较，阿托伐他汀组左心房内径增大程度低于对照组（P〈0．05），血CRP浓度比对照组降低明显（P〈0．05）。结论阿托伐他汀能通过抗炎、抑制左心房重构作用预防阵发性心房颤动复发。Objective To study the efficacy of atorvastatin for primary hypertension with paroxysmal auricular fibrillation,and its effects on LAD and CRP. Methods 80 cases of hypertension with paroxysmal atri- al fibrillation patients were selected randomly, which were divided into control group（40 cases） and atorvastatin group （40 Cases）. And the two groups take medicine for 1 year. Compared with the efficacy, LAD and CPR before and after the treatment between 2 groups. Results （1）Mter the treatment of the two groups, the efficient of control group was 38.4%, and atorvastatin group was 62. 5% （ χ^2 = 4. 56 P 〈 0. 05 ）. （2）Compard between 2 groups after treatment, LAD of the the atorvastatin group was significantly smaller than control group （ P 〈 0. 05 ）, CRP of the atorvastatin group was significantly lower than that of the contral group （P 〈 0. 05）. Conclusion The treatment with atorvastatin could prevent recurrence of paroxysmal atrial fibrillation through anti-inflammatory and inhibiting the remodeling of left atrial.

关 键 词：阿托伐他汀 胺碘酮 原发性高血压 阵发性房颤 左房内径 C反应蛋白 

分 类 号：R541.75[医药卫生—心血管疾病]